Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-08-07 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes specifics about the amount raised, the use of funds, the bank accounts involved, and compliance with regulatory requirements. The document references regulatory guidelines related to the management and use of raised funds and provides a comprehensive breakdown of the investment projects funded by the raised capital. The document length is 3868 characters, which is relatively short but contains substantive financial data about the use of raised funds, not just an announcement or a link to a report. This matches the characteristics of a Capital/Financing Update, which covers updates on company fundraising and capital usage. It is not an Annual Report, Interim Report, or Earnings Release, as it focuses specifically on the raised funds and their usage rather than overall financial performance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-07 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangdong Yongshun Biological Pharmaceutical Co., Ltd. regarding the receipt of a new veterinary drug registration certificate. It details the approval by the Ministry of Agriculture and Rural Affairs of China, the specifics of the new drug, its development background, and the impact on the company. The document is relatively short (1455 characters) and serves as a formal notification of a regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial statements, management discussion, or other report content. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a new product approval.
2023-07-26 Chinese
回购股份结果公告
Transaction in Own Shares Classification · 100% confidence The document is titled '回购股份结果公告' which translates to 'Announcement of Share Repurchase Results'. It details the company's share buyback plan, including the number of shares repurchased, prices, funding sources, implementation period, and the impact on the company. It also lists related disclosures and confirms compliance with information disclosure obligations. The document length is 3245 characters, which is relatively short and focused on announcing the results of a share repurchase program rather than providing a full financial report or detailed analysis. This matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-07-20 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the progress of a share repurchase program by Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes specifics on the repurchase plan, quantities, prices, funding sources, and progress updates as of June 30, 2023. The content focuses on the company's buyback of its own shares, including transaction details and compliance with the repurchase plan. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2023-07-02 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase (buyback) plan. It details the repurchase scheme, including the number of shares repurchased, prices, funds used, and progress as of a certain date. It does not contain financial statements or comprehensive financial analysis but focuses on the status and details of the share buyback activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares. The document length is short and specific to repurchase progress, not a full financial report or announcement of a report publication.
2023-05-31 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the completion of business scope changes and amendments to the company bylaws, as well as the completion of related industrial and commercial registration procedures and obtaining a new business license. It includes details about the company's updated registration information and legal representative. The document is short (910 characters) and does not contain financial data, audit information, or detailed reports. It is not a financial report, earnings release, or management discussion. It is an official regulatory announcement about company registration and governance changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.